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Abstract
Background: Gingivitis can develop as a reaction to dental plaque. It can be limited by curtailing plaque build-up
through actions including tooth brushing and the use of medicinal mouthwashes, such as those containing
chlorhexidine digluconate (CHX), that can reach parts of the mouth that may be missed when brushing. This study
aimed to compare dental stain control of twice-daily brushing with a sodium fluoride (NaF) dentifrice containing
67 % sodium bicarbonate (NaHCO3) or a commercially available NaF silica dentifrice without NaHCO3, while using a
mouthwash containing 0.2 % CHX.
Methods: This was a 6-week, randomised, two-site, examiner-blind, parallel-group study in healthy subjects with at
least ‘mild’ stain levels on the facial surfaces of ≥4 teeth and ≥15 bleeding sites. Assessment was via modified
Lobene Stain Index (MLSI), the score being the mean of stain intensity multiplied by area (MLSI [IxA]).
Results: One hundred and fifty of 160 randomised subjects completed the study. There were no significant differences
in Overall (facial and lingual) MLSI (IxA) scores between dentifrices. The Facial MLSI (IxA) was statistically significant
at 6 weeks, favouring the 67 % NaHCO3 dentifrice (p = 0.0404). Post-hoc analysis, conducted due to a significant site
interaction, found significant differences for all MLSI scores in favour of the 67 % NaHCO3 dentifrice at Site 1 (both
weeks) but not Site 2.
Conclusions: No overall significant differences were found between a 67 and 0 % NaHCO3 dentifrice in controlling
CHX stain; a significant difference on facial surfaces suggests advantage of the former on more accessible surfaces.
Trial registration: This study was registered at ClinicalTrials.gov (NCT01962493) on 10 October 2013 and was
funded by GSK Consumer Healthcare.
Keywords: Chlorhexidine mouthwash, Sodium bicarbonate, Dentifrice, Stain
Abbreviations: AE, Adverse events; ANCOVA, Analysis of covariance; B, Body; BI, Saxton & Van der Ouderra bleeding
index; BL, Baseline; Ca, Calcium; CHX, Chlorhexidine digluconate; CI, Confidence interval; D, Distal; Diff, Difference;
G, Gingival; GSKCH, GSK Consumer Healthcare; ITT, Intent-to-treat; IxA, Intensity multiplied by area;
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tissue; PP, Per protocol; PROPHY, Prophylaxis; RDA, Relative dentin abrasivity; SD, Standard deviation
* Correspondence: ivy.x.akwagyiram@gsk.com
1GSK Consumer Healthcare, St Georges Avenue, Weybridge, Surrey KT13 0DE,
UK
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Akwagyiram et al. BMC Oral Health  (2016) 16:79 
DOI 10.1186/s12903-016-0271-3
Background
Gingivitis, a common problem that in some can lead to
periodontitis, can develop as a reaction to dental plaque
[1]. The occurrence of gingivitis can be limited by cur-
tailing plaque build-up through actions including tooth
brushing and the use of medicinal mouthwashes that
can reach parts of the mouth that may be missed when
brushing [2, 3].
Chlorhexidine digluconate (CHX), used in dentistry
for around 40 years [3], has antibacterial properties
against both gram-positive and gram-negative species
[1, 4] including those associated with periodontal dis-
ease [5]. Following use of CHX-containing mouth-
wash, about a third of the active ingredient remains
on the teeth, pellicle, oral mucosa, tongue and in sal-
ivary proteins [3, 6], providing sustained antibacterial
properties for 8–12 h [6]. These actions, especially
when combined with tooth brushing, can lead to break up
of existing plaque, reduction of plaque re-growth and in-
hibition of the development of gingivitis [7–10].
CHX mouthwashes may be recommended by dental
professionals for use over a period of a few weeks or
months in those for whom gingivitis is problematic [10].
However, CHX is associated with significantly increased
levels of staining compared to non-CHX mouthwashes
[10, 11], which may lead to reluctance to use a CHX
mouthwash as prescribed. Adding a toothpaste with
good stain control qualities to this oral healthcare regi-
men could make the use of a CHX mouthwash more ac-
ceptable to those concerned about staining. As staining
is associated with the presence of plaque [12], measures
to try and prevent CHX staining could include use of
dentifrices with plaque-limiting ingredients. One such
ingredient is sodium bicarbonate (NaHCO3), which
works by enhancing physical removal of plaque biofilm
[13]. An added advantage of NaHCO3 is that it has very
low abrasivity [14], thus lowering potential damage
found with some stain-limiting ingredients with high
abrasivity [15].
To investigate the stain control properties of NaHCO3,
this study compared twice daily brushing with a sodium
fluoride (NaF) dentifrice containing 67 % NaHCO3 ver-
sus a commercially available NaF silica dentifrice with-
out NaHCO3 during 6 weeks use of a mouthwash
containing 0.2 % CHX.
Methods
This 6-week, randomised, single centre (Intertek Clinical
Research Services, UK), two site (Site 1: Manchester,
UK; Site 2: Maldon, UK) examiner-blind, parallel-group
study under the same Principal Investigator compared
the stain control effect of twice daily brushing with a
67 % NaHCO3-containing dentifrice versus a standard
dentifrice when both were used in combination with a
0.2 % CHX mouthwash. This study was reviewed by
the National Research Ethics Service Committee East
Midlands, Northampton. There were two protocol
amendments, both for purely administrative reasons,
of which the review committee was informed. This
study is in ClinicalTrials.gov (NCT01962493) with re-
sults published on the GSK Clinical Study Register
website [16].
During screening, subjects gave their written informed
consent to participate in the study in accordance with
the Declaration of Helsinki [17]. Demographics, medical
history and concomitant medications were recorded,
followed by an oral examination (which included an oral
soft tissue [OST] examination), gross stain assessment
and a gingival bleeding assessment (see below) to con-
firm study suitability. Subjects were 18–64 years of age,
in good general and oral health (excluding gingivitis)
with a minimum of 11 of 12 permanent gradable anter-
ior teeth and, as a means to assess the presence of gin-
givitis, a total of at least 15 bleeding sites as measured
by the Saxton & Van der Ouderra Bleeding Index (BI, a
modification of the Gingival Index) [18] where 0 = no
bleeding after 30 s, 1 = bleeding upon probing after
30 s, 2 = immediate bleeding observed; the score was
converted to bleeding (score of 1 or 2) or no bleeding
(score of 0) to determine the number of bleeding sites
in the mouth.
Following screening, eligible candidates were provided
with a standard washout dentifrice (Control dentifrice,
see below) for use at home for one timed minute twice
daily, applied in a strip to cover the head of a supplied
toothbrush (Aquafresh Clean Control Medium tooth-
brush, GSK Consumer Healthcare [GSKCH], Weybridge,
UK, to be used throughout the study) until the baseline
visit (up to 14 days after screening). At this visit subjects
underwent a full OST exam and a stain assessment
using the modified Lobene Stain Index (MLSI) on
MacPherson sites (see description below and Fig. 1).
Intra-oral digital images were taken of the relevant fa-
cial and lingual surfaces of the anterior teeth to pro-
vide a record of tooth stain before and after product
use, these were not used for stain rating. A dental
prophylaxis and floss was carried out on the anterior
teeth used to assess the stain to clean and remove all
stain to ensure they were free of all plaque and
supra- and sub-gingival calculus both visually and by
tactile assessment. Hence, all subjects had an MLSI
score of 0 prior to study treatment use. Throughout
the study the use of other oral care products includ-
ing other mouthwashes, antimicrobial lozenges, chew-
ing gums or floss (except for impacted food removal)
was not allowed.
A randomisation schedule generated by the Biostatistics
and Data Management Department of GSKCH stratified
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subjects based on site, baseline MLSI score (low Facial
MLSI <45, high Facial MLSI ≥45) and smoking status. All
subjects received mint flavour, alcohol free Corsodyl®
0.2 % mouthwash containing 0.2 % CHX (GSKCH,
Weybridge, UK). Subjects were allocated to either a
NaHCO3 dentifrice: Corsodyl® Daily Gum and Toothpaste
containing 67 % NaHCO3 and 1400 ppm fluoride as
NaF (relative dentin abrasivity [RDA] ∼47.6) (GSKCH,
Weybridge, UK) or a Control dentifrice without
NaHCO3: Aquafresh® Fresh & Minty Toothpaste contain-
ing 1450 ppm fluoride as NaF (RDA ∼93.0) (GSKCH,
Weybridge, UK). Study dentifrices were supplied in com-
mercial packaging then over-wrapped to blind study staff
and subjects to treatment assignment. CHX mouthwash
was supplied in its commercial packaging.
Subjects were instructed to apply a strip of denti-
frice to cover the toothbrush head and brush in their
usual manner for one timed minute then thoroughly
rinse their mouth with water. Five timed minutes
after brushing, subjects rinsed for one timed minute
with 10 mLs of 0.2 % CHX mouthwash. To ensure
treatment compliance, subjects’ first use of their allo-
cated products was carried out under supervision at
the site. Subjects then used their assigned product at
home twice daily for 6 weeks, with use reported on a
supplied diary card that was checked at all study
visits. At Weeks 3 and 6 ± 2 days post baseline, sub-
jects returned to the site and underwent a full OST
examination followed by stain assessments using the
MLSI index.
Objectives
The primary objective was to determine whether
brushing with a 67 % NaHCO3 dentifrice produced a
greater level of stain control than brushing with a
non-NaHCO3 dentifrice following 6 weeks usage, as
indicated by Overall (total facial and lingual) MLSI
stain Intensity multiplied by Area (IxA) scores. Sec-
ondary objectives were to compare Overall MLSI
treatment differences following 3 weeks of usage; to
compare differences between treatments on stain-
control levels after 3 and 6 weeks of treatment, as in-
dicated by the individual MLSI (IxA) scores for each
region (Overall Interproximal, Overall Facial, Overall
Gingival and Interproximal), and to monitor oral ad-
verse events (AEs) using OST examination.
Procedures and assessments
Gross stain assessment
An examination to ascertain oral health and gross level
of stain was performed. Subjects needed to have a suffi-
cient level of stain at screening to be eligible. Stain levels
on the facial surfaces of the six maxillary and six man-
dibular anterior teeth needed to be at least ‘mild’ (i.e.
mild, moderate or severe) and present on a minimum of
four teeth out of the 12 maxillary and mandibular teeth
evaluated.
MLSI using MacPherson’s sites [19, 20]
Stain was assessed on air-dried teeth by a single qualified
examiner after the subject had brushed the teeth to be
Fig. 1 Diagram of MacPherson tooth areas with MLSI grading sites on the two central upper incisors. G = Gingival; B = Body; M =Mesial; D = Distal
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assessed with water for 10 s to remove any loose debris.
Assessment was made of the area and intensity of dental
stain on the facial surfaces of the maxillary and man-
dibular anterior teeth and lingual surfaces of the man-
dibular anterior teeth, surfaces that cosmetically are the
most apparent with respect to stain accumulation. Each
surface was divided into four regions (see Fig. 1).
 Gingival (G) = a crescent-shaped band about 2 mm
wide running parallel to the gingival margin; the
limit of the G region is toward the incisal edge,
marked by the end of the interdental papilla
 Body (B) = the central area of the buccal/lingual
aspect, between G and D/M sites, extending to the
incisal edge
 Mesial (M) = the visible area of the tooth facing
toward the central midline, ending at the interdental
papilla (G site start), bordered by the B area
 Distal (D) = the visible area of the tooth facing away
from the central midline, ending at the interdental
papilla (G site start), bordered by the B area
The MLSI is derived from the products of the Intensity
and Area scores (IxA scores) of all regions.
Stain intensity
The intensity of stain was scored separately for each re-
gion using the following criteria:
0 = No stain
1 = Light stain
2 =Moderate stain
3 = Heavy stain
Stain area
The area of stain was scored separately for each region
using the following criteria:
0 = No stain
1 = Stain up to 1/3 of the area affected
2 = Stain between 1/3 and 2/3 of the area affected
3 = Stain more than 2/3 of area affected
The MLSI (IxA) scores were calculated at the site level
first and then averaged over the whole regions of interest
(Overall, Overall Interproximal, Overall Facial, Overall
Gingival and Interproximal), as detailed in Table 1.
OST assessment
The OST examination was accomplished by direct ob-
servation and palpation with retraction aids as appropri-
ate. Any post-treatment soft tissue abnormality observed
by the examiner or reported by the subject was recorded
as an adverse event.




It was planned to screen sufficient number of subjects to
randomise a maximum of 160 (80 to each treatment
group), ensuring at least 70 evaluable subjects per group
completed the Week 6 assessment, this being the num-
ber calculated to provide 90 % power to detect a differ-
ence between treatment groups of 0.364 in the MLSI
(IxA) at Week 6, assuming a standard deviation of 0.66
[21], using a two sample t-test with a 0.05 two-sided sig-
nificance level.
The primary population for assessment of efficacy was
the intent-to-treat (ITT) population, defined as those
Table 1 Relevant tooth site for calculation of MLSI score
Variable Surfaces Region Summary
(Average over)
Overall MLSI Max-F, Man-F,
Man-L (18)
GBMD (4) 18 × 4 = 72 sites










GMD (3) 18 × 3 = 54 sites
Max-F maxillary-facial, Man-F mandibular-facial, Man-L mandibular-lingual,
G gingival, B body, M mesial and D distal
Table 2 Summary of the demographics and baseline







Male n (%) 22 (28.2 %) 22 (26.8 %)
Female n (%) 56 (71.8 %) 60 (73.2 %)
Mean age (±SD) 39.8 (11.08) 39.5 (10.87)
Age range 19–64 18–63
Ethnicity n (%) White 56 (71.8) 69 (84.1)
Black 9 (11.5) 5 (6.1)
Asian 9 (11.5) 2 (2.4)
Multiple 4 (5.1) 6 (7.3)
Smoker n (%) Yes 18 (23.1) 18 (22.0)
No 60 (76.9) 64 (78.0)
Total facial MLSI
(IxA) score n (%)
Low (<45) 72 (92.3) 72 (87.8)
High (≥45) 6 (7.7) 10 (12.2)
Mean Bleeding Index (±SD) 0.5 (0.50) 0.5 (0.50)
Mean Overall MLSI (IxA) (±SD)a 0.78 (0.710) 0.74 (0.610)
Site n (%) 1 49 (62.8) 50 (61.0)
2 29 (37.2) 32 (39.0)
aFrom ITT population (n = 75, 79); n number, SD standard deviation
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who received study treatment and had at least one post-
baseline efficacy measurement. Analysis of Covariance
(ANCOVA) was used to analyse the MLSI (IxA) at
Weeks 3 and 6. The model included treatment, site and
smoking status as factors and the relevant baseline MLSI
(IxA) score as a covariate. A factor for treatment by
study site interaction was included and retained in the
model as it was significant at the 10 % level. Since the
treatment by site interaction was significant, a post-hoc
analysis by study site was carried out with factors for
treatment and smoking status and baseline as a covari-
ate. Residuals from the model showed departures from
normality and a square root transformation improved
the distribution and was applied to the data. Resulting
means and confidence intervals (CIs) were back trans-
formed [22].
Assessment of examiner
Weighted Kappa coefficients, along with 95 % CIs, were
calculated to assess the intra-examiner repeatability for
MLSI (IxA) assessments at each visit. Repeatability was
deemed to represent excellent replication if the kappa
coefficient was greater than 0.75, fair to good replication
if the value was between 0.4 and 0.75 inclusive and poor
replication if the value was below 0.4.
Results
Baseline summary
In total, 314 subjects were screened and 160 were rando-
mised (99 at Site 1, 61 at Site 2), of whom 150 com-
pleted the study. All 160 subjects were treated so were
included in the Safety population. Their mean age was
39.6 (range 18–64), they were mainly female (72.5 %),
white (78.1 %) and non-smokers (77.5 %). Most subjects
had a facial MLSI (IxA) score at baseline of <45 (90.0 %)
with a mean baseline BI score of 0.5, comparable for
each group (Table 2).
Of the 160 subjects, six provided no post-baseline
efficacy data leading to an ITT population of 154 (95 at
Site 1, 59 at Site 2). Fourteen of the 160 subjects had
protocol violations leading to total exclusion and a
Per Protocol (PP) population of 146 (Fig. 2). Due to
similar numbers between ITT and PP populations
(<10 % difference), PP analysis was not performed.
The study was carried out between 16 September
2013 and 20 November 2013.
Fig. 2 Trial profile. PP = Per Protocol; ITT = Intent-to-treat
Table 3 Summary of treatment differences in MLSI regions by
week (ITT population n = 154)
Region Week Difference (95 % CI)b % Diffb P-value
Overall MLSI 3 −0.09 (−0.24, 0.06) −22.6 0.1552
6a −0.20 (−0.51, 0.10) −19.9 0.1313
Overall Facial MLSI 3 −0.09 (−0.20, 0.01) −39.2 0.0529
6 −0.23 (−0.49, 0.02) −32.2 0.0404
Overall Interproximal
MLSI
3 −0.13 (−0.36, 0.09) −22.0 0.1873
6 −0.28 (−0.74, 0.18) −18.4 0.1713
Overall Gingival and
Interproximal MLSI
3 −0.12 (−0.31, 0.07) −22.8 0.1614
6 −0.23 (−0.60, 0.15) −18.2 0.1709
aPrimary objective; bDiff difference is 67 % NaHCO3 dentifrice minus control
dentifrice. A negative difference favours the former. Results are based on back
transformed data based on square root transformation; bold text indicates a
statistically significant value
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Efficacy results
For all comparisons, the 67 % NaHCO3 dentifrice had
numerically lower MLSI scores than the Control denti-
frice. However, there was no significant difference be-
tween treatments for the primary efficacy variable of
Overall MLSI at 6 weeks (−19.9, P = 0.1313). The Overall
Facial MLSI was significantly different at Week 6, favour-
ing the 67 % NaHCO3 dentifrice (−32.2 %, P = 0.0404)
(Table 3, Fig. 3).
There was a significant treatment site interaction; a
post-hoc investigation of the data by site showed differ-
ent treatment effects at each (Table 4; Fig. 4).
At Site 1, for Overall MLSI (IxA) score at both 3
and 6 weeks there were significant differences of −52.1 %
(P = 0.0016) and −41.2 % (P = 0.0072) in favour of the
67 % NaHCO3 dentifrice group. However, no such signifi-
cant differences were seen at Site 2 for either week. Simi-
larly, all secondary efficacy variables were significantly
different for Site 1 and none were significantly different
at Site 2.
Repeatability
The repeatability analysis of the MLSI Index (based on
30 subjects) showed excellent agreement between the
first and repeat assessments for both area and intensity.
The weighted kappa value for MLSI-Area was 0.91
(95 % CI = 0.89, 0.93) and MLSI-Intensity was 0.92
(95 % CI = 0.90, 0.94).
Safety results
Overall, 80 subjects (50.0 %) reported at least one AE,
with a total of 142 AEs. All of the 31 treatment-related
AEs reported by 28 subjects (17.5 %) were oral AEs
(Table 5). Three subjects withdrew due to AEs; two in
the Control group: one due to dysgeusia and one due to
glossodynia, and one subject from the 67 % NaHCO3
dentifrice group due to appendicitis and ruptured ovar-
ian cyst. There were three serious AEs reported by two
subjects: one had autoimmune pancreatitis, reported
pre-treatment, and one had appendicitis and a ruptured
ovarian cyst, reported during the study. None of these
AEs were treatment related.
Fig. 3 Unadjusted Overall MLSI score by treatment time (± standard error). BL = Baseline; PROPHY = Prophylaxis; MW=Mouthwash; MLSI =modified
Lobene Stain Index
Table 4 Summary of treatment differences by site (ITT population
n = 154)
Site Week Difference (95 % CI) % Diffa P-value
Overall MLSI
1 3 −0.26 (−0.43, −0.09) −52.1 0.0016
6 −0.44 (−0.77, −0.10) −41.2 0.0072
2 3 0.08 (−0.16, 0.31) 22.6 0.4621
6 0.05 (−0.44, 0.54) 5.5 0.8038
Facial overall MLSI
1 3 −0.19 (−0.32, −0.06) −64.8 0.0019
6 −0.40 (−0.68, −0.12) −53.0 0.0032
2 3 0.00 (−0.17, 0.17) 1.2 0.9757
6 −0.04 (−0.45, 0.36) −6.4 0.8105
Overall interproximal MLSI
1 3 −0.36 (−0.62, −0.10) −49.7 0.0043
6 −0.61 (−1.12, −0.10) −39.2 0.0126
2 3 0.10 (−0.25, 0.45) 19.4 0.5421
6 0.09 (−0.65, 0.83) 6.0 0.7888
Overall gingival and interproximal MLSI
1 3 −0.31 (−0.53, −0.09) −51.0 0.0029
6 −0.50 (−0.91, −0.09) −39.6 0.0108
2 3 0.08 (−0.21, 0.38) 19.0 0.5409
6 0.09 (−0.52, 0.69) 6.9 0.7550
aDiff = Difference is 67 % NaHCO3 dentifrice minus control dentifrice. A
negative difference favours 67 % NaHCO3 dentifrice. Results based on back
transformed data based on square root transformation; bold text indicates a
statistically significant value.
Akwagyiram et al. BMC Oral Health  (2016) 16:79 Page 6 of 9
Discussion
Studies have shown that CHX-containing mouthwash is
an effective way to reduce gingivitis [7, 9]. However,
people may be reluctant to use CHX mouthwash as pre-
scribed as it can cause tooth staining [10, 11]. As stain-
ing levels are associated with plaque occurrence, one
way to help counteract stain is by minimising plaque
build-up through, for instance, the use of NaHCO3-con-
taining dentifrice, which can help physically remove
plaque biofilm [13, 23].
In this study, stain accumulation at 6 weeks was higher
than had been seen at baseline, suggesting that indeed
CHX use led to increased levels of staining. While the
67 % NaHCO3 dentifrice group showed a numerically
lower level of stain compared to the Control dentifrice
group, the difference in Overall MLSI (IxA) (a combined
measure of maxillary and mandibular facial and man-
dibular lingual staining) was not significant at either 3 or
6 weeks. The Overall Facial MLSI was statistically sig-
nificantly different at Week 6, favouring the 67 %
NaHCO3 dentifrice. This was the only measure to ex-
clude the lingual surface, which is of interest as the facial
surfaces are known to be easier to clean than the lingual
ones.
To examine factors that may have led to a finding
of non-significance overall, the study results were
broken down by site in a post-hoc analysis. For Site 1
there were significant differences favouring the 67 %
NaHCO3 dentifrice at both weeks and for all areas in-
cluding overall MLSI; this was not shown for Site 2.
Examiner variations were ruled out as the same
examiner was used at both sites and the same hygien-
ist carried out the majority of the prophylaxes at both
sites. The randomisation process and storage condi-
tions of the study supplies were also checked and no
issues found. There were differences in the clinical
suite lighting: Site 1 used a 5000 K bulb, Site 2 a
3550 K bulb, but this was not thought to affect as-
sessments as there were similarities in baseline data
between study sites. Another factor could be that
there was a difference in the consumption of stain-
causing drinks by site; however, the fact that baseline
staining and Week 6 control dentifrice values were
very similar may not support this postulate.
A factor of interest was that there was a difference in
water hardness with Site 1 (Manchester) classified as
‘very soft’ (average 9.3 milligrams/litre calcium [mg/l
Ca]) [24] and Site 2 (Maldon) as ‘hard to very hard’
Fig. 4 Mean Overall MLSI score by treatment, study site (centre) and time (unadjusted means ± standard error). BL = Baseline; PROPHY = Prophylaxis;
MW=Mouthwash; MLSI =modified Lobene Stain Index






+ MW (N = 82)
n (%) nAE n (%) nAE
All AEs 39 (50.0) 70 41 (50.0) 72
Oral AEs 21 (26.9) 24 33 (40.2) 43
Treatment Related AEs 11 (14.1) 12 17 (20.7) 19
Treatment-related oral AEs
Dysgeusia 1 (1.3) 1 7 (8.5) 7
Paraesthesia oral 3 (3.8) 3 4 (4.9) 4
Glossodynia 2 (2.6) 2 3 (3.7) 4
Tongue discolouration 4 (5.1) 4 0 0
Ageusia 1 (1.3) 1 2 (2.4) 2
Sensitivity of teeth 1 (1.3) 1 1 (1.2) 1
Hypoaesthesia oral 0 0 1 (1.2) 1
MW mouthwash; n (%) number (percent) of subjects with at least one AE;
nAE number of adverse events
Akwagyiram et al. BMC Oral Health  (2016) 16:79 Page 7 of 9
(range 98–120 mg/l Ca) [25]. It was queried as to
whether or not this could have affected the results. An
in vitro study showing that staining intensity with a
combination of tea and CHX mouthwash was greater
with hard water [26] would mean that this current study
should have had higher Week 6 staining levels with the
Control dentifrice at Site 2, which was not the case;
hence, any differences could be due to potential inter-
action factors between water hardness and the effective-
ness of NaHCO3 as opposed to being due to interactions
with the CHX mouthwash.
Conclusion
In summary, no significant difference in stain levels was
found between a dentifrice containing NaHCO3 and one
without this ingredient when using a mouthwash con-
taining 0.2 % CHX. Differences were seen in facial sur-
face staining after 6 weeks, suggesting effectiveness of
NaHCO3 dentifrice on more accessible surfaces. As dif-
ferences were seen at different sites, further investigation
may be warranted.
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